|
|
| Line 32: |
Line 32: |
| **[[6sq0]] - hERα LBD (mutant) + indole derivative<br /> | | **[[6sq0]] - hERα LBD (mutant) + indole derivative<br /> |
| **[[6v8t]] - hERα LBD (mutant) + benzothiophene derivative<br /> | | **[[6v8t]] - hERα LBD (mutant) + benzothiophene derivative<br /> |
| **[[6vjd]], [[6vmu]], [[6vpf]], [[6vpk]], [[6vvp]] - hERα LBD + modulator<br /> | | **[[6vjd]], [[7ujf]], [[6vpf]], [[6vpk]], [[6vvp]] - hERα LBD + modulator<br /> |
| **[[6vgh]] - hERα LBD (mutant) + modulator<br /> | | **[[6vgh]] - hERα LBD (mutant) + modulator<br /> |
| **[[5t1z]] - hERα LBD + LXXLL motif (mutant) + ethoxy triphenylethylene<br /> | | **[[5t1z]] - hERα LBD + LXXLL motif (mutant) + ethoxy triphenylethylene<br /> |
Updated on 15-June-2022 - For a general description of the protein see Estrogen receptor
{"openlevels":0}
- Estrogen receptor α ligand binding domain residues 245-554
- 1a52, 1g50 - hERα LBD - human
- 1ere, 1qku - hERα LBD + EST
- 1qkt - hERα LBD (mutant) + EST
- 1uom, 2ayr, 2q70, 2qe4, 2pog, 2r6w, 2r6y, 2qxs, 5u2b, 5tn9, 5tnb - hERα LBD (mutant) + ligand
- 1err, 3ert, 1sj0, 1yim, 1r5k, 1xp1, 1xp6, 1xp9, 1xpc, 1xqc, 1yin, 2ouz, 2iog, 2iok, 3dt3, 3os8, 3os9, 3osa, 5t92, 5t97 - hERα LBD + ligand
- 4xi3 - hERα LBD + bazedoxifene
- 2bj4, 2jf9, 2jfa, 1pcg, 5gtr, 5gs4 - hERα LBD + peptide antagonist
- 2q6j, 2p15, 3erd, 1l2i - hERα LBD + GRIP peptide
- 6d0f, 6cbz, 6czn - hERα LBD (mutant) + GRIP peptide
- 6cbz, 5wgq, 5wgd - hERα LBD (mutant) + GRIP peptide + EST
- 6pit - hERα LBD (mutant) + stapled peptide + EST
- 4q13 - hERα LBD (mutant) + glucocorticoid receptor-interacting protein peptide
- 7ujo - hERα LBD + anti-hormone
- 7uj7 - hERα LBD (mutant) + anti-hormone
- 5krf - hERα LBD (mutant) + peptide + anti-hormone
- 2yat - hERα LBD (mutant) + EST derivative
- 6iar, 6dfn, 6df6, 6zoq, 6zor, 6zos, 7msa - hERα LBD + antagonist
- 5fqp, 5fqr, 5fqs, 5fqt, 5fqv, 5aau, 5aav, 5acc, 5ak2, 5di7, 5did, 5die, 5dig, 5dk9, 5dkb, 5dke, 5dkg, 5dks, 5dl4, 5dlr, 5dmc, 5dmf, 5dp0, 6chz, 6chw, 6c42, 6b0f, 5w9d, 5ufx, 5ufw - hERα LBD (mutant) + antagonist
- 6owc - hERα LBD (mutant) + pyridine derivative
- 4q50, 5w9c, 6v87 - hERα LBD (mutant) + tamoxifen derivative
- 3uuc - hERα LBD + bisphenol
- 6pet - hERα LBD + hydroxychromene
- 6pfm - hERα LBD (mutant) + hydroxychromene
- 6psj, 6vgh, 6vpk, [6vvp]], 7kca, 7kcd, 7kbs - hERα LBD (mutant) + osteoporosis drug
- 6wok - hERα LBD + breast cancer drug
- 6suo - hERα LBD + indole derivative
- 6sq0 - hERα LBD (mutant) + indole derivative
- 6v8t - hERα LBD (mutant) + benzothiophene derivative
- 6vjd, 7ujf, 6vpf, 6vpk, 6vvp - hERα LBD + modulator
- 6vgh - hERα LBD (mutant) + modulator
- 5t1z - hERα LBD + LXXLL motif (mutant) + ethoxy triphenylethylene
- 1gwr - hERα LBD + TIF2 peptide + EST
- 2ocf - hERα LBD (mutant) + fibronectin domain 10 + EST
- 2yja - hERα LBD + NCAO2 peptide
- 2b23 - hERα LBD (mutant) + NCAO2 peptide
- 4n1y - ERα LBD – pacific oyster
- ERα LBD ternary complex with nuclear receptor coactivator 2 peptide (NCAO2)
- 2yja - hERα LBD + NCAO2 peptide
- 5hyr, 5dx3, 5dxb, 4pxm, 3q95 - hERα LBD (mutant) + NCAO2 peptide + estradiol
- 5dxb - hERα LBD (mutant) + NCAO2 peptide + stilbestrol derivative
- 4zn7 - hERα LBD + NCAO2 peptide + benzylidene estrone
- 5kri, 5krj, 5krk, 5krl, 5krm, 5kro - hERα LBD (mutant) + NCAO2 peptide + anti-hormone
- 5egv, ehj, 5ei1, 5eit, 5dxk, 5dxe, 5dxg, 5kro - hERα LBD (mutant) + NCAO2 peptide + anti-hormone
- 7jhd - hERα LBD + NCAO2 peptide + antagonist
- 5dxe, 5dxg, 5dxk, 5dxm, 5dxp, 5dxq, 5dxr, 5dy8, 5dyb, 5dyd, 5dz0, 5dz1, 5dz3, 5dzh, 5dzi, 5e0w, 5e0x, 5e14, 5e15, 5e19, 5e1c, 5drj, 5drm, 5dtv, 5du5, 5due, 5dug, 5duh, 5dvs, 5dvv, 5dwe, 5dwg, 5dwi, 5dwj, 4iu7, 4iui, 4iv2, 4iv4, 4ivw, 4ivy, 4iw6, 4iw8, 4iwc, 4iwf, 5u2d, 5tld, 5tlf, 5tlg, 5tll, 5tlm, 5tlo, 5tlp, 5tlt, 5tlu, 5tlv, 5tlx, 5tly, 5tm1, 5tm2, 5tm3, 5tm4, 5tm5, 5tm6, 5tm7, 5tm8, 5tm9, 5tml, 5tmo, 5tmm, 5tmq, 5tmr, 5tms, 5tmt, 5tmu, 5tmv, 5tmw, 5tmz, 5tn1, 5tn3, 5tn4, 5tn5, 5tn6, 5tn7, 5tn8, 5ehj - hERα LBD (mutant) + NCAO2 peptide + antagonist
- 5kcf, 5kct, 5kcu, 5kcw, 5kd9, 5kcc, 5kcd, 5kce, 4zn9, 4znh, 4zns, 4znt, 4znu, 4znv, 4znw - hERα LBD (mutant) + NCAO2 peptide + OBHS derivative
- 5kr9 - hERα LBD (mutant) + NCAO2 peptide + coumestrol
- 2g5o - hERα LBD + NCAO2 peptide + EST derivative
- 2qgt, 5krh, 5krc, 5kra - hERα LBD (mutant) + NCAO2 peptide + EST derivative
- 1gwq, 2fai, 2g44, 2qzo - hERα LBD + NCAO2 peptide + ligand
- 3l03, 3hm1, 3hlv, 1zky, 2b1v, 2b1z, 2qa6, 2qab, 2qgw, 2qh6, 2qr9, 2qse, 2qxm - hERα LBD (mutant) + NCAO2 peptide + ligand
- 2qa8 - hERα LBD (mutant) + NCAO2 peptide + genistein
- 4pp6, 4ppp, 4pps - hERα LBD (mutant) + NCAO2 peptide + resveratrol derivative
- ERα LBD ternary complex with steroid receptor coactivator 1 peptide
- 3uu7, 3uua, 3uud - hERα LBD (mutant) + NCAO1 peptide
- 4dma - hERα LBD (mutant) + NCAO1 peptide + inhibitor
- 4mg5, 4mg6, 4mg7, 4mg8, 4mg9, 4mga, 4mgb, 4mgc, 4mgd - hERα LBD (mutant) + NCAO1 peptide + ligand
- 4tuz - hERα LBD (mutant) + NCAO1 peptide + toxin
- 4tv1 - hERα LBD (mutant) + NCAO1 peptide + preservative
- 5jmm - hERα LBD (mutant) + NCAO1 peptide + biochanin
- ERα LBD ternary complex with steroid receptor coactivator 2 peptide
- 2b23 - hERα LBD (mutant) + NCAO2 peptide
- 3q95 - hERα LBD (mutant) + NCAO2 peptide + EST
- 4iu7, 4iui, 4iv2, 4iv4, 4ivw, 4ivy, 4iw6, 4iw8, 4iwc, 4iwf, 5u2d, 5tld, 5tlf, 5tlg, 5tll, 5tlm, 5tlo, 5tlp, 5tlt, 5tlu, 5tlv, 5tlx, 5tly, 5tm1, 5tm2, 5tm3, 5tm4, 5tm5, 5tm6, 5tm7, 5tm8, 5tm9, 5tml, 5tmo, 5tmm, 5tmq, 5tmr, 5tms, 5tmt, 5tmu, 5tmv, 5tmw, 5tmz, 5tn1, 5tn3, 5tn4, 5tn5, 5tn6, 5tn7, 5tn8 - hERα LBD (mutant) + NCAO2 peptide + inhibitor
- 2g5o - hERα LBD + NCAO2 peptide + EST derivative
- 2qgt - hERα LBD (mutant) + NCAO2 peptide + EST derivative
- 5kce - hERα LBD (mutant) + NCAO2 peptide + OBHS derivative
- 1gwq, 2fai, 2g44, 2qzo - hERα LBD + NCAO2 peptide + ligand
- 3l03, 3hm1, 3hlv, 1zky, 2b1v, 2b1z, 2qa6, 2qab, 2qgw, 2qh6, 2qr9, 2qse, 2qxm - hERα LBD (mutant) + NCAO2 peptide + ligand
- 2qa8 - hERα LBD (mutant) + NCAO2 peptide + genistein
- 4pp6, 4ppp, 4pps - hERα LBD (mutant) + NCAO2 + resveratrol derivative
- ERα LBD ternary complex with steroid receptor coactivator 3 peptide
- 1x7r - hERα LBD + NCAO3 peptide + genistein
- 1x7e - hERα LBD + NCAO3 peptide + ligand
- Estrogen receptor α DNA binding domain
- 1hcp – hERα DBD – NMR
- 1hcq, 4aa6 – hERα DBD + DNA
- 6sbo – hERα residues 124-381 + pyrrolydin derivative
- Estrogen receptor β ligand binding domain
- 1qkm - hERβ LBD + genistein
- 1qkn, 1hj1 - ERβ LBD + ligand – rat
- 1nde, 1u3q, 1u3r, 1u3s, 2giu, 2i0g, 2i0j, 2jj3, 2z4b, 2qtu, 5toa - hERβ LBD + ligand
- 2yly - hERβ LBD + sulfonamide agonist
- 2fsz - hERβ LBD (mutant) + ligand
- 2yja, 2yjd - hERβ LBD + NCAO peptide
- 4zi1 - hERβ LBD + NCAO5 peptide + antagonist
- 4j24, 4j26 - hERβ LBD + peptide
- ERβ LBD ternary complex with steroid receptor coactivator peptide
- 1l2j - hERβ LBD + NCAO peptide + nonsteroidal EST
- 2j7x, 3oll, 3ols - hERβ LBD + NCAO peptide + EST
- 1u9e - hERβ LBD + NCAO peptide
- 1x76, 1x78, 1x7b, 1yy4, 1yye, 1zaf, 2j7y, 2nv7, 3omo, 3omp, 3omq - hERβ LBD + NCAO peptide + ligand
- 1x7j - hERβ LBD + NCAO peptide + genistein